http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2149631-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-382
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
filingDate 1995-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2000-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bd25e25b337cb0b42b5ca47c97514fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f42fa76e7baeb05212b4052ccfbe978
publicationDate 2000-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2149631-C1
titleOfInvention Method of inhibition of osteoporosis, pharmaceutical preparation for osteoporosis inhibition
abstract FIELD: medicine. SUBSTANCE: method involves administration to humans of 2-phenyl-3-aroylbenzothio-phene and bis-phosphonate or their acceptable salts or solvates. Alendronate, pomidronate, risedronate, cycloheptyl-aminomethylidene bis-phosphonate and others can be used as bis-phosphonate. [6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thiene-3-yl]-[4-[2-(1-piperidinyl)ethoxy] phenyl]-methanone, its salts and solvates and others compounds are used as 2-phenyl-3-aroyl-benzothiophene. Pharmaceutical preparation has 2-phenyl-3-aroylbenzothiophene and bis-phosphonate or their acceptable salts or their solvates. Combined administration of compounds of two indicated types enhances effectiveness of treatment and decreases possible undesirable adverse effects. Invention can be used for treatment of patients with osseous disorders, in part, with postclimacteric and senile osteoporosis. EFFECT: enhanced effectiveness of treatment, decreased adverse effects. 9 cl, 10 tbl
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7745482-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-008474-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7459568-B2
priorityDate 1994-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465157379
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163561832

Total number of triples: 48.